Download Files:
Tariquidar (methanesulfonate, hydrate)
$58 – $490
Products Details
Product Description
– Tariquidar methanesulfonate, hydrate (XR9576 methanesulfonate, hydrate) is a potent and specific inhibitor of P-glycoprotein (P-gp) with a Kd of 5.1 nM.
Web ID
– HY-10550A
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C40H52N4O15S2
Citations
– J Cereb Blood Flow Metab. 2020 Jan;40(1):150-162.|Mol Imaging Biol. 2019 Apr;21(2):257-268. |Mol Pharm. 2020 Sep 8;17(9):3477-3486.|Nucl Med Biol. 2018 May;60:29-36. |RWTH Aachen University. 2021 Oct.|Antimicrob Agents Chemother. 2015 Nov 30;60(2):946-54. |Antioxidants (Basel). 2021 Jun 11;10(6):949.|Antiviral Res. 2021 Jun 28;105124.|Cell Death Discov. 2021 Aug 5;7(1):204.|Cell. 2023 Nov 14:S0092-8674(23)01176-5.|Crit Rev Anal Chem. 2021 Mar 10;1-15.|Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):599-606.|Eur J Med Chem. 2017 Feb 15;127:586-598. |Eur J Med Chem. 2018 Mar 10;147:7-20. |Eur J Pharm Sci. 2019 Jan 15;127:319-329.|Int J Mol Sci. 2022, 23(23), 14948.|Int J Mol Sci. 2023 Mar 10.|J Biomed Nanotechnol. 2018 Oct 1;14(10):1705-1718.|J Cereb Blood Flow Metab. 2016 Aug;36(8):1412-23. |J Cereb Blood Flow Metab. 2021 Jul;41(7):1634-1646.|J Control Release. 2022 Jul 8;349:109-117.|J Drug Deliv Sci Technol. May 2022, 103323.|J Nanopart Res. (2018) 20:176.|J Nat Prod. 2022 Nov 22.|Langmuir. 2015 May 12;31(18):5115-22. |Mar Drugs. 2022, 20(10), 597.|Mar Drugs. 2022, 20(12), 738|Mar Drugs. 2023 Mar 14.|Mar Drugs. 2023, 21(1), 54.|Mol Pharm. 2019 Mar 4;16(3):1282-1293. |Mol Pharm. 2021 Jan 4;18(1):416-428.|Pharm Res. 2017 Jan;34(1):148-160.|Pharmaceuticals. 2023 Feb 24; Feb 16(3), 349.|Pharmaceutics. 2021 Feb 26;13(3):306.|PLoS One. 2017 Sep 15;12(9):e0183662. |Research Square Preprint. 2021 Mar.|Research Square Print. 2022 Jul.|RSC Adv. 2016,6, 69083-69093.|Sci Bull. 2016 Apr;61(7):552-560.|Sci Rep. 2017 Dec 22;7(1):18069.|Sci Rep. 2022 Aug 9;12(1):13570.|Small. 2020 Nov;16(44):e2004172.|Xenobiotica. 2020 Mar;50(3):354-362. |J Control Release. 2021 Dec 28;342:44-52.
References
– [1]Mistry P, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res, 2001, 61(2), 749-758.|[2]Martin C, et al. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br J Pharmacol, 1999, 128(2), 403-411.|[3]Vraka C, et al. A new method measuring the interaction of radiotracers with the human P-glycoprotein (P-gp) transporter. Nucl Med Biol. 2018 Feb 14;60:29-36.
CAS Number
– 625375-83-9
Molecular Weight
– 892.99
Compound Purity
– 98.38
SMILES
– O=C(C1=CC2=CC=CC=C2N=C1)NC3=CC(OC)=C(OC)C=C3C(NC4=CC=C(CCN5CC6=C(C=C(OC)C(OC)=C6)CC5)C=C4)=O.CS(=O)(O)=O.CS(=O)(O)=O.O.O.O
Clinical Information
– Phase 3
Research Area
– Cancer
Solubility
– DMSO : ≥ 296 mg/mL|H2O : 5.56 mg/mL (ultrasonic;warming;heat to 70°C)
Target
– P-glycoprotein
Pathway
– Membrane Transporter/Ion Channel
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
